0000000000921969
AUTHOR
A. Molino
High redshift galaxies in the ALHAMBRA survey
International audience
The ALHAMBRA survey: An empirical estimation of the cosmic variance for merger fraction studies based on close pairs
[Aims]: Our goal is to estimate empirically the cosmic variance that affects merger fraction studies based on close pairs for the first time. [Methods]: We compute the merger fraction from photometric redshift close pairs with 10 h−1 kpc ≤ rp ≤ 50 h−1 kpc and Δv ≤ 500 km s−1 and measure it in the 48 sub-fields of the ALHAMBRA survey. We study the distribution of the measured merger fractions that follow a log-normal function and estimate the cosmic variance σv as the intrinsic dispersion of the observed distribution. We develop a maximum likelihood estimator to measure a reliable σv and avoid the dispersion due to the observational errors (including the Poisson shot noise term). [Results]: …
The ALHAMBRA survey: Accurate merger fractions by PDF analysis of photometric close pairs
Our goal is to develop and test a novel methodology to compute accurate close pair fractions with photometric redshifts. We improve the current methodologies to estimate the merger fraction f_m from photometric redshifts by (i) using the full probability distribution functions (PDFs) of the sources in redshift space, (ii) including the variation in the luminosity of the sources with z in both the selection of the samples and in the luminosity ratio constrain, and (iii) splitting individual PDFs into red and blue spectral templates to deal robustly with colour selections. We test the performance of our new methodology with the PDFs provided by the ALHAMBRA photometric survey. The merger frac…
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age 35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks tra…